Some GLP-1s Achieve More Weight Loss Than Others

"Yes, I am on a GLP-1 for a weight-loss medication,” the 'Queer Eye' star said
“Alright, I have a confession to make. Yes, I am on a GLP-1 for a weight-loss medication,” Van Ness said.
Some GLP-1s Achieve More Weight Loss Than Others: Study
Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap
GLP-1 Drugs For Weight Loss Aren’t Cost-Saving Yet
Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug spending. But thus far, the data don’t show this.
How do GLP-1 drugs work for weight loss?
Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame themselves for it.
The most and least expensive weight loss drugs, ranked
Sales of blockbuster weight-loss drugs have surged in 2024 and are projected to continue rising in the coming years. The medications, which belong to the class of drugs called GLP-1s and were popularized by the diabetes treatment Ozempic,
How do GLP-1s boost weight loss and heart health?
Weight loss tops many folks' list of New Year's resolutions, and lots of people are turning to cutting-edge weight-loss drugs like Ozempic to help them drop excess pounds.
Less than 50% of employers cover GLP-1 drugs for weight loss: JPM survey
"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated that almost 50 million adults in employer plans meet the clinical criteria for taking such drugs, which can cost thousands of dollars annually per person," according to a report from Kaiser Family Health (KFF) in October.
Which State Medicaid Programs Cover GLP-1s for Weight Loss & How Much Are They Spending?
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high costs—often exceeding $1,000 per month—put them out of reach for many Americans whose
GLP-1s cut surgery complication risk in some patients: Study
Glucagon-like peptide-1 receptor agonist drugs may reduce the risk of surgical complications in diabetic patients, according to a large new study. The study showed diabetic patients taking GLP-1 drugs,
GLP-1 RAs Efficacious for Weight Loss in Overweight, Obesity Without Diabetes
For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published online Jan. 7 in the Annals of Internal Medicine.
Medscape2d
GLP-1s: The Key to Meet BMI Cutoff for Orthopedic Surgery?
Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.
As demand for weight-loss drugs rises, states grapple with Medicaid coverage
Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...
Fierce Healthcare23h
Found introducing oral dissolvable GLP-1 tablet at reduced price
Weight management platform Found is today launching oral semaglutide dissolvable tablets for individuals looking for ...
Medscape1d
Retatrutide Produces Greatest Weight Loss
Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...
Newport Beach Independent15h
Bariatric Surgeons Face Decline As GLP-1s Gain Ground In Obesity Treatment
Recent market research reveals that glucagon-like peptide-1 (GLP-1) injections are set to dominate the obesity treatment ...
Circana Report Highlights the Role of Personalization in Supporting GLP-1 Weight-Loss Users
GLP-1 weight-loss users shift their spending on food purchases both in and out of home. At grocery retail, they are spending more on foods that support GLP-1 balance, including vegetables, eggs and ...
‘Ozempic’s biggest night’: How weight loss drugs showed up at the 2025 Golden Globes
Just eight seconds into the start of the 2025 award show season, Nikki Glaser, the host of the 82nd Golden Globes, dubbed the ...
Medscape6d
Docs Worry Not Enough Known About GLP-1s and Teens
Eighty percent of doctors in a Medscape survey answered no when asked, “Is enough known about obesity meds’ risk to ...